Ampio Pharmaceuticals (AMPE)
OTHER OTC:AMPE
Want to see AMPE full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Low Leverage
Low leverage indicates that the company has not overburdened itself with debt, which can be advantageous in maintaining financial flexibility and reducing risk during periods of financial distress.
Negative Factors
Zero Revenue
The lack of revenue generation over an extended period highlights significant challenges in commercializing products, which is critical for sustaining operations and achieving profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Low leverage indicates that the company has not overburdened itself with debt, which can be advantageous in maintaining financial flexibility and reducing risk during periods of financial distress.
Read all positive factors
Ampio Pharmaceuticals (AMPE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$207.88K
Dividend YieldN/A
Average Volume (3M)1.58K
Price to Earnings (P/E)―
Beta (1Y)27.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,135,358
10 Day Avg. Volume4,379
30 Day Avg. Volume1,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap-17.35
Enterprise Value/Revenue-14.72
Enterprise Value/Gross Profit-14.72
Enterprise Value/Ebitda0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ampio Pharmaceuticals Business Overview & Revenue Model
Company Description
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injecti...
How the Company Makes Money
Ampio Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's earnings are largely dependent on the successful clinical development, regulatory approval, and subse...
Ampio Pharmaceuticals Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -250.00K | -2.08M | -1.09M | -1.18M | -1.27M |
| EBITDA | -8.38M | -23.16M | -15.98M | -14.59M | -12.28M |
| Net Income | -8.63M | -16.34M | -17.07M | -15.89M | -13.63M |
Balance Sheet | |||||
| Total Assets | 5.74M | 13.59M | 38.83M | 22.88M | 14.00M |
| Cash, Cash Equivalents and Short-Term Investments | 4.09M | 12.65M | 33.89M | 17.35M | 6.53M |
| Total Debt | 274.00K | 803.00K | 1.19M | 1.21M | 1.47M |
| Total Liabilities | 2.38M | 1.80M | 11.54M | 5.37M | 7.56M |
| Stockholders Equity | 3.36M | 11.79M | 27.28M | 17.51M | 6.44M |
Cash Flow | |||||
| Free Cash Flow | -8.56M | -21.13M | -14.19M | -14.79M | -15.40M |
| Operating Cash Flow | -8.56M | -21.13M | -14.09M | -14.73M | -15.38M |
| Investing Cash Flow | 0.00 | 0.00 | -97.00K | -63.00K | -22.00K |
| Financing Cash Flow | 0.00 | -111.00K | 30.73M | 25.61M | 14.35K |
Ampio Pharmaceuticals Risk Analysis
Ampio Pharmaceuticals disclosed 9 risk factors in its most recent earnings report. Ampio Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ampio Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $207.88K | -0.02 | -256.90% | ― | ― | ― | |
46 Neutral | $243.47M | -0.25 | -1028.81% | ― | ― | 61.43% | |
45 Neutral | $5.47M | -0.74 | -203.36% | ― | ― | 93.30% | |
44 Neutral | $1.66M | -0.13 | ― | ― | 99.50% | -426.19% |
* Healthcare Sector Average
AMPE
Ampio Pharmaceuticals
0.18
0.05
40.77%
SCNI
Scinai Immunotherapeutics
0.48
-1.91
-79.96%
INDP
Indaptus Therapeutics
2.15
-7.59
-77.93%
PMCB
PharmaCyte Biotech
0.75
-0.35
-31.73%
ADTX
Aditxt
0.11
-37,344.13
-100.00%
DRMA
Dermata Therapeutics
1.36
-5.68
-80.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―